证券日报网讯1月23日，浙江震元（000705）在互动平台回答投资者提问时表示，公司投资的绍兴普华 震元创业投资合伙企业(有限合伙)未投资火箭发射及回收企业"箭元科技"。 ...

吴海明表示，绍兴这片水土不仅孕育了独特的古越文明，也催生了在中华医药史上占据重要一席的"越 医药"体系。越医研制了世界上第一个非处方药，编撰了中国第一部由国家颁行的成药专著和配方手 册。这份独特的文化底蕴，成为浙江震元诞生与成长的沃土。 从清乾隆十七年（1752年）间绍兴水澄巷的一间小药铺起步，成长为一家集医药工业、商业与健康服务 于一体的现代化企业，浙江震元的成长密码既深植于古越文化的沃土，也源于其在时代浪潮中持续不断 的自我革新。 浙江震元党委书记、董事长吴海明近日在接受上海证券报记者专访时表示，公司在坚守医药主业与越医 药文化传承的同时，正积极以科技赋能传统，在合成生物等新赛道上开启全新征程。未来，浙江震元将 深化体制机制改革，激发老字号的发展活力，推动企业实现高质量发展。 弥新：千年越医源远流长 作为百年老字号，浙江震元何以穿越时代，始终屹立？ 在吴海明看来，答案来自三股相互交织的力量：越地文化的深厚滋养为企业奠定了根基；对越地医药文 化的坚守与传承撑起了它的脊梁；勇于突破、持续创新的气质，赋予了企业不断向前的生命力。 ◎记者 严曦梦 千年越医，百年震元。 越医源于春秋，兴于唐宋，盛于明清。清乾隆十七 ...

格隆汇1月22日丨浙江震元(000705.SZ)在投资者互动平台表示，公司目前没有赖氨酸产品。 ...

格隆汇1月22日丨浙江震元(000705.SZ)在投资者互动平台表示，公司S2生产线计划今年投产，暂未规划 其他生产线。 ...

Core Viewpoint - Zhejiang Zhenyuan (000705) is actively engaging in the production of amino acids using synthetic biology technology, with positive market feedback on its current products [1] Group 1: Company Developments - The subsidiary Zhejiang Zhenyuan Biotechnology Co., Ltd. has launched histidine and hydrochloride histidine into the market, receiving favorable responses [1] - The S2 production line is scheduled to commence operations this year, indicating the company's commitment to expanding its production capabilities [1] - The company plans to gradually introduce additional amino acid products based on research and market demand [1]

Core Viewpoint - The pharmaceutical commercial sector experienced a slight increase of 0.39% on January 19, with significant contributions from stocks like Dajia Weikang, which led the gains [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4114.0, up by 0.29%, while the Shenzhen Component Index closed at 14294.05, up by 0.09% [1] - Dajia Weikang (301126) led the sector with a closing price of 13.91, reflecting a rise of 6.43% and a trading volume of 162,500 shares, amounting to a transaction value of 220 million yuan [1] - Other notable performers included Dacianlin (603233) with a 4.37% increase, Guofang Co. (600538) up by 3.27%, and Yifeng Pharmacy (603939) rising by 2.55% [1] Group 2: Fund Flow Analysis - The pharmaceutical commercial sector saw a net outflow of 436 million yuan from institutional investors, while retail investors contributed a net inflow of 486 million yuan [2] - The individual stock fund flow indicated that Ruikang Pharmaceutical (002589) had a net inflow of 19.77 million yuan from institutional investors, while it faced a net outflow of 17.52 million yuan from retail investors [3] - Dajia Weikang (301126) also experienced a net inflow of 13.40 million yuan from institutional investors, despite a net outflow of 15.06 million yuan from retail investors [3]

每经AI快讯，有投资者在投资者互动平台提问：从近期走势来看是不是公司四季度出现大额亏损？公 司一直在宣传合成生物转型是不是出现了重大问题？ （文章来源：每日经济新闻） 浙江震元（000705.SZ）1月8日在投资者互动平台表示，公司生物定向合成项目S1产线于2025年8月30日 投产，目前结合市场需求逐步释放产能。 ...

（记者 王晓波） 每经AI快讯，有投资者在投资者互动平台提问：S1生产线已经投产一个季度，S2生产线正在调试，企 业向生物制造行业正在转型，想了解一下S1生产线共计投入多少？四季度产能达产多少？按照市场需 求预计2026年能够产生销售收入多少？能贡献利润多少？S2生产线大概何时调试能够完成？ 浙江震元（000705.SZ）1月8日在投资者互动平台表示，公司生物定向合成项目预计总投资58704.37万 元。S1生产线结合市场需求逐步释放产能，产销情况良好。S2生产线按工程进度安排推进中，计划 2026年投产。 ...

（文章来源：证券日报） 证券日报网讯 12月30日，浙江震元在互动平台回答投资者提问时表示，公司组氨酸自投产以来，结合 市场需求安排生产计划，产销情况良好。 ...

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.0% on December 30, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3965.12, also down by 0.0%, while the Shenzhen Component Index rose by 0.49% to 13604.07 [1] Stock Performance - Notable gainers in the pharmaceutical sector included: - Yingte Group (000411) with a closing price of 13.23, up by 9.98% and a trading volume of 419,800 shares [1] - Yao Yigou (300937) at 35.65, up by 7.64% with 125,700 shares traded [1] - HeFu China (603122) at 26.00, up by 6.17% with a trading volume of 985,200 shares [1] - Conversely, Saily Medical (603716) saw a decline of 3.19% to a closing price of 20.95, with a trading volume of 123,200 shares [2] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 258 million yuan from institutional investors, while retail investors contributed a net inflow of 54.61 million yuan [2] - Notable capital flows included: - HeFu China (603122) with a net inflow of 286 million yuan from institutional investors [3] - Yingte Group (000411) with a net inflow of 134 million yuan from institutional investors [3] - Yao Yigou (300937) with a net inflow of 16.36 million yuan from institutional investors [3]